View Archive »
About The Cover
The cover for issue 61 of Oncotarget features Figure 3, "The effect of loss of CD38 on blood vessels, necrotic area, peritumoral area and amount of CAFs in late stage tumors effect on blood vessels density," by Baruch, et al.
|
|
Table of Contents
News
|
| Stem cells: a window of opportunity in lowdimensional EMT space |
|
https://doi.org/10.18632/oncotarget.25852
|
| 31790-31791 |
|
| A potential novel option for cancer immunotherapy – TLR7 stimulation inhibits malignant melanoma bone invasion |
|
https://doi.org/10.18632/oncotarget.25872
|
| 31792-31792 |
|
| A new twist to VATPases and cancer |
|
https://doi.org/10.18632/oncotarget.25883
|
| 31793-31794 |
Editorial
|
| Implementation of cancer treatment during pregnancy in daily practice: the important role of perinatologists |
|
https://doi.org/10.18632/oncotarget.25841
|
| 31795-31796 |
Priority Research Papers
|
| Stromal CD38 regulates outgrowth of primary melanoma and generation of spontaneous metastasis |
|
https://doi.org/10.18632/oncotarget.25737
|
| 31797-31811 |
Research Papers
|
| Immunologically effective dose: a practical model for immunoradiotherapy |
|
https://doi.org/10.18632/oncotarget.25746
|
| 31812-31819 |
|
| Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX |
|
https://doi.org/10.18632/oncotarget.25806
|
| 31820-31831 |
|
| LEE011 and ruxolitinib: a synergistic drug combination for natural killer/Tcell lymphoma NKTCL |
|
https://doi.org/10.18632/oncotarget.25835
|
| 31832-31841 |
|
| cMET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors |
|
https://doi.org/10.18632/oncotarget.25867
|
| 31842-31860 |
|
| Real life triplet FIr/FOx chemotherapy in firstline metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study |
|
https://doi.org/10.18632/oncotarget.25870
|
| 31861-31876 |
|
| Everolimus EVE and exemestane EXE in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study |
|
https://doi.org/10.18632/oncotarget.25874
|
| 31877-31887 |
|
| Acquired resistance to BRAFi reverses senescencelike phenotype in mutant BRAF melanoma |
|
https://doi.org/10.18632/oncotarget.25879
|
| 31888-31903 |
|
| Investigation of appropriate preanalytical procedure for circulating free DNA from liquid biopsy |
|
https://doi.org/10.18632/oncotarget.25881
|
| 31904-31914 |
Reviews
|
| Dual targeting of HER2positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results |
|
https://doi.org/10.18632/oncotarget.25739
|
| 31915-31919 |
|
| Virus and tumor microenvironment induced ER stress and unfolded protein response: from complexity to therapeutics |
|
https://doi.org/10.18632/oncotarget.25886
|
| 31920-31936 |
Corrections
|
| Correction: Consumption of fruits and vegetables and risk of renal cell carcinoma: a metaanalysis of observational studies |
|
https://doi.org/10.18632/oncotarget.25969
|
| 31937-31937 |
|
| Correction: A genetic variant in SLC28A3 rs56350726 is associated with progression to castrationresistant prostate cancer in a Korean population with metastatic prostate cancer |
|
https://doi.org/10.18632/oncotarget.25970
|
| 31938-31938 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
